Skip to main content
. 2014 Dec 1;30(10):847–853. doi: 10.1089/jop.2014.0021

FIG. 3.

FIG. 3.

Effect of tanibirumab on the regression of laser-induced CNV measured by intravenously injected FITC-dextran. (A) CNV areas of the RPE-choroid-sclera flat mounts were compared between tanibirumab-treated and control eyes. (B, C) On day 14, the mean CNV areas, as measured by intravenously injected FITC-dextran, were significantly smaller in tanibirumab-treated eyes (5, 20, and 60 μg/2 μL of PBS) than in PBS-injected eyes (n=8; P=0.038, P=0.003, and P<0.001, respectively, by the Mann–Whitney U-test). Human IgG-injected eyes showed no difference compared with PBS-injected eyes. *P<0.05. Scale bar denotes 100 μm.